Nova Mentis is a Canadian listed (CSE, FSE) company that holds two subsidiaries, Nova Mentis Biotech and Pilz BioSciences that investigate psychedelics as medicines for a variety of mental health indicators.
Nova Mentis
Nova Mentis Biosciences is focused on obesity, diabetes, and liver disease (NASH).
Pilz Biosciences is working on Autism Spectrum Disorder (ASD), for which they have launched a clinical study in May 2021.
The company was formally named Liberty Leaf Holdings (with a focus on the cannabis market).
Nova Mentis is listed on the CNSX under the ticker NOVA.
“We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.“
Activities
B2B
B2C
Pharmaceutical
Biotech
Topics of Interest
Autism
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
EMA Grants Nova Mentis Life Sciences Corp’s Fragile X Syndrome Psilocybin Drug Orphan Drug Status (, 15 April 2024)Nova Mentis to Present at the H.C. Wainwright Psychedelics Conference (, 03 December 2021)
Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical Program (, 16 December 2021)